The 8th Annual International Meeting for Autism Research (IMFAR) will host more than 1500 researchers, delegates, autism specialists, and students in the world’s largest gathering of researchers and clinicians devoted to a better understanding of autism. The meeting is being held at the Hilton Chicago Hotel from May 6-9, 2009. Meeting sponsors include Autism Speaks, the Simons Foundation, the Autism Society of America and the National Institutes of Health.
Lees meer..

Academic Press, a division of Elsevier, would like to announce the new second edition of Essentials of Stem Cell Biology edited by Robert Lanza, John Gearhart, Brigid Hogan, Douglass Melton, Roger Pedersen, E. Donnall Thomas, James Thomason and Ian Sir Wilmut. This book serves the needs of the evolving population of scientists, researchers, practitioners and students that are embracing the latest advances in adult and embryonic stem cell research.
Lees meer..

Eli Lilly and Company (NYSE: LLY) announced results from a double-blind, placebo-controlled study which showed that tadalafil 5 mg dose taken once daily was generally well-tolerated, improved erectile function for men with erectile dysfunction (ED) and reported improvement in the sexual quality of life scores for men and their female partners.
Lees meer..

D-Pharm announced that it has submitted IND and Special Protocol Assessment (SPA) packages to the US Food and Drug Administration (FDA), for its pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients. D-Pharm plans to initiate the trial later this year following FDA review of the IND and SPA. Recently, D-Pharm also obtained Scientific Advice from the European Medicines Agency (EMEA) on the development strategy for DP-b99 in Europe.
Lees meer..

Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce the launch of a set of clinical trials following the signature of an exclusive and worldwide licence agreement on July 10th 2008 with the University of Bordeaux.
Lees meer..

Paloma Pharmaceuticals, Inc. presented “Palomid 529, An Inhibitor of the Akt/mTOR Pathway Reduces Photoreceptor Cell Death Following Experimental Retinal Detachment”, at the annual meeting of the Association for Research in Vision and Ophthalmology 2009 (ARVO 2009), This study, presented by Geoffrey P. Lewis, Ph.D. (along with G. Luna, J. Byun, E.A. Chapin and S.K.
Lees meer..

Pfizer Inc., a major biopharmaceutical company, and the Wisconsin Alumni Research Foundation (WARF), the private, nonprofit patenting and licensing organization for the University of Wisconsin-Madison, announced May 5 that they have signed a license for human embryonic stem (hES) cell patents for the development of new drug therapies. The WARF license provides Pfizer the rights to work with hES cells for drug research and discovery.
Lees meer..

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the US Food and Drug Administration (FDA) has granted marketing approval of Fanapt(TM) (iloperidone) for the acute treatment of adult patients with schizophrenia. The approval was supported by two placebo-controlled Phase III clinical studies comparing Fanapt(TM) to placebo and active control in patients with schizophrenia, as well as safety data from more than 3,000 patients.
Lees meer..

The US Food and Drug Administration (FDA) has approved Fanapt tablets (iloperidone) made by Patheon Inc of Mississauga, Ontario, for Vanda Pharmaceuticals Inc of Rockville, Maryland, for the treatment of adults with schizophrenia, said an announcement on the FDA website on Wednesday. The news that Vanda has won US approval for its first product sent shares in the company soaring in extended Nasdaq Stock Market trading yesterday, said the Washington Post.
Lees meer..

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced that FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression), a clinical trial designed to examine the impact of 500mg of varespladib when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event, met its primary endpoint of a reduction in Low Density Lipoprotein Cholesterol (LDL-C).
Lees meer..